Bulletin
Investor Alert

Corbus Pharmaceuticals Holdings Inc.

NAS: CRBP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 1, 2021, 7:59 p.m.

/zigman2/quotes/201549545/composite

$

2.43

Change

+0.03 +1.25%

Volume

Volume 71,087

Quotes are delayed by 20 min

/zigman2/quotes/201549545/composite

Previous close

$ 2.18

$ 2.40

Change

+0.22 +10.09%

Day low

Day high

$2.23

$2.46

Open

52 week low

52 week high

$0.91

$9.78

Open

Yuval Cohen

Yuval Cohen founded Celsus Therapeutics Plc. He is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer & Director at Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.).

In the past Yuval Cohen was Director & Senior Vice President at Celsus Therapeutics Plc.

Dr. Cohen received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V.

Transactions

Date Shares Transaction Value
11/11/2020 4,240   Acquisition at $1.21 per share. 5,130
03/17/2020 4,300   Acquisition at $3.49 per share. 15,007
11/12/2019 1,430   Acquisition at $4.26 per share. 6,091
08/12/2019 1,175   Acquisition at $6.06 per share. 7,120
05/13/2019 995   Acquisition at $6.99 per share. 6,955
03/14/2019 1,530   Acquisition at $6.49 per share. 9,929
05/15/2018 1,725   Acquisition at $5.85 per share. 10,091
03/14/2018 1,160   Acquisition at $6.88 per share. 7,980
11/10/2017 1,000   Acquisition at $7.17 per share. 7,170
08/11/2017 1,695   Acquisition at $6 per share. 10,170
05/11/2017 3,250   Acquisition at $6.01 per share. 19,532
03/16/2017 20,000   Derivative/Non-derivative trans. at $1 per share. 20,000
11/22/2016 1,340   Acquisition at $7.64 per share. 10,237
08/17/2016 20,000   Derivative/Non-derivative trans. at $1 per share. 20,000
06/06/2016 1,500   Acquisition at $3.34 per share. 5,010
05/18/2016 2,125   Acquisition at $2.4 per share. 5,100

Officers and Executives

Dr. Yuval Cohen
Chief Executive Officer & Director
Mr. Sean F. Moran
Chief Financial & Accounting Officer
Dr. Barbara White
Chief Medical Officer
Dr. Sergei Atamas
Executive Director-Research
Mr. Craig Millian
Chief Commercial Officer
Mr. Ross Lobell
Vice President-Regulatory Affairs
Mr. Alan F. Holmer
Chairman
Dr. Peter Salzmann
Independent Director
Mr. Avery W. Catlin
Independent Director
Dr. John Kenneth Jenkins
Independent Director
Ms. Rachelle Jacques
Independent Director
Link to MarketWatch's Slice.